AndroGel Side-Effect Reports from Real Users

Where These Reports Come From and Why They Matter

User-reported side effects fill a gap that randomized trials leave open: what testosterone gel feels like in daily life, not just what lab values show at scheduled study visits. Forum posts on r/Testosterone, r/trt, and Drugs.com review pages represent thousands of uncontrolled, self-selected narratives. They are not epidemiological evidence.

Selection bias runs in both directions. People who tolerate a medication well may never post. People with dramatic negative reactions post frequently. A 2020 analysis in the Journal of Medical Internet Research found that online drug reviews skew toward extreme experiences, both positive and negative, compared to the distribution seen in controlled trials [2]. That context matters for everything below.

Still, the volume is useful. Drugs.com alone hosts over 200 user reviews specifically for testosterone topical products, and Reddit's r/Testosterone community exceeds 250,000 members. When the same complaint surfaces across dozens of independent accounts, it signals a pattern worth comparing against clinical data. The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials enrolling 790 men aged 65 and older with low testosterone, documented the efficacy and side-effect profile of 1% testosterone gel in a rigorous setting [3]. The real-user data below is consistently measured against that benchmark.

Skin Reactions: The Side Effect Almost Everyone Mentions

Application-site irritation is the most frequently cited side effect in both clinical trials and user forums. It is also the least surprising. AndroGel contains alcohol-based carriers that evaporate on contact, and the residual gel base can cause local redness, itching, or a mild rash.

In the TTrials, application-site reactions occurred in approximately 4.1% of the testosterone gel group vs. 2.5% of placebo [3]. Online reports suggest the real-world incidence feels higher. One r/Testosterone user described it plainly: "First two weeks my shoulders looked sunburned every morning. It calmed down after switching to my upper thighs." Another Drugs.com reviewer wrote: "The itching at the application site was so bad I almost quit. My doctor told me to rotate sites daily, and that mostly fixed it."

The Endocrine Society's 2018 clinical practice guideline for testosterone therapy recommends rotating application sites and allowing the gel to dry completely before covering with clothing [4]. Users who follow this guidance consistently report reduced irritation within the first month. Those who apply gel to the same site daily, or who cover the area immediately, report persistent problems.

Contact dermatitis, a more severe allergic reaction, is rare but documented. The FDA prescribing information for AndroGel 1.62% lists it as an uncommon adverse reaction [5]. Users who develop true contact dermatitis typically require a switch to injectable testosterone or a different topical formulation.

Acne and Oily Skin: A Predictable Androgenic Effect

Acne ranks as the second most discussed side effect on Reddit and Drugs.com. The mechanism is straightforward: exogenous testosterone increases sebum production, which can clog pores. This effect is dose-dependent and tends to peak during the first 8 to 12 weeks of therapy before stabilizing.

The prescribing information for AndroGel 1.62% lists acne as occurring in 2 to 8% of clinical trial participants [5]. User reports suggest the lived experience is more variable. Some men describe severe cystic acne on their back and shoulders. Others report mild breakouts that resolve without treatment. A Drugs.com reviewer rated the drug 3/10 and wrote: "I'm 48 years old and I have worse acne now than I did at 16. Mostly on my back and chest."

Dermatologic management during TRT initiation is straightforward. The American Academy of Dermatology recommends benzoyl peroxide wash (5%) for mild to moderate hormonal acne, with topical retinoids added if needed [6]. Dose reduction may be appropriate when acne is severe and serum testosterone levels are above the therapeutic target of 400 to 700 ng/dL.

Hematocrit and Polycythemia: The Lab Value Users Watch Closely

Testosterone stimulates erythropoiesis. That is a pharmacological fact, not a side effect in the traditional sense, but it becomes a clinical concern when hematocrit exceeds 54%, the threshold at which the Endocrine Society recommends dose reduction or temporary cessation [4]. In the TTrials, men in the testosterone group showed a mean increase in hematocrit of approximately 2.5 percentage points over 12 months [3].

On r/Testosterone and r/trt, elevated hematocrit is one of the most discussed lab abnormalities. Users frequently share blood work results and compare notes. A common pattern: a user posts labs showing hematocrit at 52 to 53%, asks whether therapeutic phlebotomy is necessary, and receives a mix of anecdotal advice and guideline-based recommendations.

The clinical answer is clear. The 2018 Endocrine Society guideline states: "We recommend against testosterone therapy in men who have hematocrit above 48% until the cause is identified and treated, and we recommend checking hematocrit at baseline, at 3 to 6 months, and then annually" [4]. Phlebotomy is appropriate when hematocrit exceeds 54% and symptoms (headache, visual changes, paresthesias) are present.

Users who report regular blood monitoring and proactive dose adjustments describe the best outcomes. Those who skip lab work or ignore rising hematocrit report more anxiety, headaches, and one-off emergency department visits for symptoms later attributed to polycythemia.

Mood Changes and Psychological Effects

Mood-related side effects generate some of the most detailed and emotionally charged user reports. Irritability, anxiety, emotional flatness, and mood swings appear across forums with significant frequency. They also represent the area where self-report is most difficult to interpret.

Testosterone has well-documented effects on mood. The TTrials' Vitality Trial showed that testosterone gel modestly improved mood and depressive symptoms compared to placebo in men over 65 with low testosterone, as measured by the Positive and Negative Affect Schedule and the Patient Health Questionnaire-9 [7]. But "improved mood on average" does not mean every individual experiences improvement.

User reports reveal a bimodal pattern. Many men describe significant mood improvement during the first several months. "Fog lifted" and "motivation came back" are recurring phrases on r/Testosterone. But a subset of users report the opposite: increased irritability, shorter temper, or a feeling of emotional instability. One Drugs.com reviewer wrote: "Week 3, I snapped at my wife over nothing. I've never done that. Lowered my dose and it stopped."

These reports are consistent with the pharmacology. Supraphysiologic testosterone levels can increase irritability, while physiologic replacement typically improves well-being. The clinical takeaway: mood side effects during TRT often signal a dosing issue rather than a fundamental intolerance. Serum testosterone trough levels should be checked, and dose titration should target the mid-normal range (450 to 600 ng/dL) rather than the upper limit.

Sleep Disruption and Its Connection to Hematocrit

Insomnia and fragmented sleep appear in roughly 10 to 15% of Drugs.com reviews for testosterone topical products. The relationship between testosterone and sleep is bidirectional and complex.

Testosterone therapy can worsen obstructive sleep apnea (OSA). The Endocrine Society guideline recommends screening for OSA before initiating TRT and lists severe untreated sleep apnea as a relative contraindication [4]. A 2014 meta-analysis of testosterone trials found a small but statistically significant increase in sleep-disordered breathing events with testosterone therapy (OR 1.46 to 95% CI 0.98 to 2.17), though the confidence interval crossed 1.0 [8].

User reports cluster into two categories. The first group describes difficulty falling asleep or frequent awakenings, sometimes linked to elevated hematocrit or the timing of gel application. Applying testosterone gel in the morning, which mimics the natural diurnal rhythm of testosterone secretion, is the standard recommendation. Users who apply gel at night report worse sleep outcomes.

The second group reports dramatic sleep improvement on TRT, often attributing it to resolution of low-T symptoms like night sweats and restlessness. This tracks with the TTrials' finding that testosterone gel improved self-reported sleep quality modestly in hypogonadal older men [3].

Cardiovascular Concerns: What Users Fear vs. What Data Shows

Cardiovascular risk is the side effect that generates the most anxiety in online communities, and it is the area where the gap between user perception and clinical evidence is widest. Many AndroGel users reference the 2010 TOM trial (Testosterone in Older Men with Mobility Limitations), which was stopped early due to increased cardiovascular events in the testosterone group [9]. That trial enrolled frail, elderly men with high baseline cardiovascular risk, making its results difficult to generalize.

The definitive answer came from the TRAVERSE trial (Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy Response in Hypogonadal Men), published in the New England Journal of Medicine in 2023. TRAVERSE randomized 5,246 men aged 45 to 80 with hypogonadism and pre-existing or high risk for cardiovascular disease to 1.62% testosterone gel or placebo. At a median follow-up of 33 months, the incidence of major adverse cardiovascular events (MACE) was 7.0% in the testosterone group vs. 7.3% in the placebo group (HR 0.96 to 95% CI 0.78 to 1.17) [1].

Dr. Shalender Bhasin, the lead investigator, stated: "The findings provide reassurance that testosterone replacement therapy in middle-aged and older men with hypogonadism and cardiovascular disease or cardiovascular risk does not increase the risk of major adverse cardiac events" [1].

This data has not fully penetrated the user community. Posts on r/Testosterone asking "will TRT give me a heart attack?" remain common in 2026. The appropriate clinical response is to cite TRAVERSE directly and to emphasize that monitoring hematocrit, blood pressure, and lipids remains standard of care.

Secondary Exposure: The Gel-Specific Risk

AndroGel carries an FDA black-box warning about secondary exposure, meaning the risk of transferring testosterone to women or children through skin contact [5]. This is not a side effect of taking the drug. It is a safety hazard of the formulation.

User reports of secondary exposure are rare on forums but carry outsized clinical significance. Virilization in female partners (deepened voice, acne, increased body hair) and precocious puberty in children have been documented in FDA adverse event reports [10]. The prescribing information mandates that patients wash hands after application, cover the application site with clothing, and wash the site before skin-to-skin contact.

Reddit users who discuss this risk often mention switching to injectable testosterone specifically to eliminate transfer concerns when they have young children in the household. That is a clinically reasonable decision.

Comparing User Reports to Clinical Trial Data

The overlap between real-world reports and clinical trial findings is substantial but imperfect. Clinical trials capture application-site reactions, hematocrit changes, PSA elevation, and headache at defined frequencies. User forums amplify subjective experiences (mood, energy, sleep, libido fluctuations) that trials measure with blunt instruments or not at all.

The Endocrine Society's 2018 guideline recommends monitoring the following during testosterone therapy: serum testosterone levels at 3 and 6 months then annually, hematocrit at the same intervals, PSA at baseline and per screening guidelines, bone density after 1 to 2 years in men with osteoporosis, and liver function if clinically indicated [4]. Users who adhere to this monitoring schedule report catching problems (especially hematocrit elevation) early and adjusting before symptoms develop.

A pattern visible across hundreds of user reports: the men who describe the best outcomes work closely with an endocrinologist or urologist, test blood work every 3 to 6 months, and titrate doses based on trough levels. The men who describe the worst outcomes self-medicate, skip monitoring, or receive prescriptions from providers who do not check follow-up labs.

What the FDA Label Says vs. What Users Experience

The AndroGel 1.62% prescribing label lists the following adverse reactions occurring in greater than or equal to 2% of patients: application-site reactions (5.2%), PSA increase (4.2%), emotional lability (2.9%), headache (2.4%), hypertension (2.2%), and acne (2.1%) [5]. The label also notes less common events: gynecomastia, peripheral edema, and increased serum creatinine.

User reviews confirm most of these but add texture. "PSA increase" on a label is abstract. On a forum, it becomes a man describing the anxiety of a rising PSA, the follow-up biopsy that found nothing, and the relief of learning the elevation was pharmacological. The Endocrine Society notes that testosterone therapy typically raises PSA by 0.3 to 0.5 ng/mL within the first 6 to 12 months, and that increases exceeding 1.4 ng/mL above baseline warrant urologic evaluation [4].

Gynecomastia (breast tissue enlargement) appears in user reports less often than acne or skin irritation but generates significant distress. The mechanism involves peripheral aromatization of testosterone to estradiol. Users on r/Testosterone frequently discuss managing estradiol levels with aromatase inhibitors like anastrozole, though the Endocrine Society does not recommend routine co-prescription of aromatase inhibitors during TRT unless clinical gynecomastia develops [4].

How to Minimize Side Effects: Guidance from Evidence and Experience

Dose titration matters more than any single intervention. The Endocrine Society recommends targeting serum testosterone in the mid-normal range (400 to 700 ng/dL) and adjusting the dose based on trough levels drawn 2 to 4 hours after gel application, at least 14 days after initiation or dose change [4].

Application technique also matters. Applying gel to clean, dry skin on the shoulders, upper arms, or abdomen (depending on the formulation), allowing 5 to 10 minutes of drying time before dressing, and washing hands immediately afterward reduces both skin irritation and transfer risk. Users who apply gel post-shower on dry skin report fewer skin reactions than those who apply to sweaty or broken skin.

Blood monitoring is non-negotiable. The monitoring schedule recommended by the Endocrine Society (testosterone, hematocrit, PSA, and lipid panel at 3 to 6 months and annually thereafter) exists because the most dangerous side effects of testosterone therapy, polycythemia and prostate stimulation, are silent until detected by lab work [4]. The first hematocrit check should occur at 3 months. If hematocrit exceeds 54%, withhold testosterone until it falls below 50% and restart at a lower dose.